Resources
We’ve put together a selection of valuable resources, designed to provide education and support for both nuclear medicine professionals and their patients. From online courses to handy patient guides, our resources are here to assist our partners and those they care for.
The Curium Way
Curium’s purpose, mission, vision and values are firmly built around people – patients, physicians, employees and society as a whole. In this video, Curium employees working in a variety of functions within the organization discuss what inspires them and how their personal purpose aligns with the Curium Way.
Curium’s World Class Manufacturing Facilities
Curium’s vertically-integrated manufacturing network is the largest in the radiopharmaceutical industry, including a molybdenum processing facility, 1 PET facility, 4 large SPECT facilities and 44 PET and SPECT nuclear pharmacies across the United States and Europe. Watch this video to learn more about how our global manufacturing network supports 14 million patients every year.
Understanding Nuclear Medicine
Our bodies have a story to tell and Nuclear Imaging is a vital tool in understanding each story and helping to diagnose disease. At Curium, we focus on delivering our products to over 35,000 patients who are in need of crucial diagnosis and treatment every day.
Curium’s commitment to Nuclear Medicine
Curium is 100% invested in Nuclear Medicine. Watch this video to learn about our 100% commitment to reliability, quality assurance, and integrated production process.
La place du PET-PSMA au Quotidien en 2024
In December 2024, a post-university symposium was held at the American Hospital of Paris (Neuilly), bringing together a panel of experts including radiologists, radiotherapists, oncologists, urologists, and nuclear medicine specialists. Through clinical case discussions, the symposium highlighted the role of PSMA in patient management.
Please note: this symposium was conducted in French.
Can we afford to ignore PSMA PET in the daily management of patients with prostate cancer?
In a recent webinar, Dr. Paolo Castellucci and Prof. Lorenzo Bianchi highlighted the growing role of PSMA PET imaging in prostate cancer care. They emphasized its value in refining staging, guiding treatment, and detecting recurrence, arguing that PSMA PET should be seen as an essential tool in everyday clinical management, not just select cases.
Please note: this symposium was conducted in English.
Bilan d'extension du cancer de la prostate, utilisation du TEP scan
In collaboration with HealthMe, Prof. Morgan Rouprêt and Dr. Charles Merlin discuss the value and current indications of PSMA PET for patients with prostate cancer.
Please note: this podcast is in French.
Intérêt de l'imagerie nucléaire suite à une récidive biologique après traitement de 1ère ligne
In collaboration with HealthMe, Prof. Morgan Rouprêt and Dr. Léa Turpin discuss the value of PSMA following first-line treatment for patients with prostate cancer.
Please note: this podcast is in French.
Intérêt du TEP-Scan dans le bilan d'extension et la stratification de la maladie métastatique hormono-sensible
This French-language podcast explores the differences between bone scintigraphy and PSMA PET, and discusses the impact of these imaging modalities on patient management. It also highlights the role of artificial intelligence in calculating tumor volumes.
Please note: this podcast is in French.
Place de la médecine nucléaire dans le bilan d'extension initial
In this French-language podcast, Prof. Morgan Rouprêt and Dr. Thibaut Cassou Mounat discuss the 2024–2025 recommendations on PSMA. They explore its impact on diagnosis and treatment decisions compared with conventional assessments.
Please note: this podcast is in French.
Interview with experts at EAU25 (1)
Catch a quick expert interview highlighting key insights and the latest scientific developments from EAU25 in Madrid.
Interview with experts at EAU25 (2)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (3)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (4)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (5)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (6)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (7)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (8)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (9)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Interview with experts at EAU25 (10)
Discover key scientific insights from EAU25 in Madrid through this quick expert interview.
Why is PSMA PET here to stay - EANM 2024 satellite symposium replay
Practical insights from one urologist and two nuclear medicine physicians’ routine work with Patients with Prostate Cancer
TEP/TDM au Fluorure de Sodium (18F-FNa) dans l'imagerie du rachis après arthrodèse - 6 dec 2022
Led by Dr. David Ziai, Dr. Clément Thomas, and Dr. Yacine El Yaagoubi, this webinar presents the value of 18F-FNa in spine imaging after arthrodesis. It highlights the role of 18F-FNa PET in complementing MRI to improve postoperative assessment and diagnostic accuracy. (Webinar held in French.)
Prostate, PSMA, Théranostic : what else ?
Presented by Dr. Mathieu Gauthé and Dr. Marion Tempier, this webinar reviews the value and current indications of PSMA PET for patients with prostate cancer. It highlights the role of PSMA in diagnosis and its advantages compared to other imaging modalities. (Webinar held in French.)
Patient Education (U.S.)
We are pleased to offer introductory nuclear imaging guides for patients and their families. Select a Nuclear Imaging topic:
- A Patient’s Guide: What is Nuclear Medicine
- A Patient’s Guide to Cardiac Stress/Rest Imaging
- A Patient’s Guide to Neuroendocrine Tumor Imaging
- A Patient’s Guide to Renal Imaging
- A Patient’s Guide to Brain Imaging
- A Patient’s Guide to Bone Imaging
- A Patient’s Guide to Liver Imaging
This information is intended for technologists based in the US.
Online CE courses (U.S.)
We offer a robust catalog of online CE courses on a variety of imaging and development topics.
These courses are structured in a self-paced learning format and can be conveniently accessed 24 hours a day, 7 days a week. All courses are approved for Category A ARRT credit and recognized by American Healthcare Radiology Administrators (AHRA) and Florida Department of Health Bureau of Radiation control (AHRA/FLDOH-BRC). Courses are offered free of charge to the participant.
This service is only available to technologists based in the US.
Continuing education for technologists (U.S.)
We offer a wide variety of continuing education (CE) programs that focus on the needs of nuclear medicine technologists.
Leader-led CE courses:
Leader-led courses are presented by a knowledgeable member of our Curium North American sales team. Live delivery of these interactive courses allows for group discussion and question and answer sessions with participants. These programs can be held on-site at your facility or at a third-party location of your choice. Our CE courses are accredited by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) VOICE and are offered at no cost to the participant. The courses offered cover a wide range of imaging topics.
This service is only available to technologist based in the U.S.
Xenon Gas Directions for use (U.S.)
Learn more about our Xenon Gas products and directions for use. Xenon XE 133 Gas and XenotronTM Xenon (Xe133) Gas Dispenser approved for use in US.
Expanded Access Program (U.S.)
Expanded access is a general term used to refer to a variety of regulatory mechanisms available to provide treatment access to patients with a life-threatening or severely debilitating disease for whom commercially available therapies or diagnostics have failed or are not available.
Production by CURIUM PET France
Every night, CURIUM PET France employees invest in producing radiopharmaceuticals to improve patient care on a daily basis. In this video, you will see the key stages of the production.